Objective Oral squamous cell carcinoma (OSCC) is a common and poor prognosis malignant tumor. Cancer stem cells (CSCs) have the potentials of self-renewal and differentiation, and they play key roles in cancer development and treatment. Epithelial cell transformation sequence 2 (ECT2), as a multifunctional oncogene, can regulate cell cycle, signaling pathways, and epigenetic modifications, and it plays a central role in tumorigenesis and development. The aim of this study was to explore the role of ECT2 in affecting the stemness maintenance of oral squamous carcinoma cells and to provide a basis for developing new therapeutic approaches for oral squamous carcinoma. Methods Big data analysis of TCGA and GEO databases were combined to determine that ECT2 was associated with oral squamous carcinoma stemness, and the expression level and clinical prognostic value of ECT2 were evaluated. Overexpression and knockdown ECT2 cell lines were constructed using lentiviral infection, and tumor spheroid formation in vivo and migration in vitro assays of oral squamous carcinoma were performed. Results ECT2 was highly expressed in oral squamous carcinoma and its level was correlated with poor patient prognosis. By overexpressing and knocking down ECT2 in oral squamous carcinoma, we revealed that ECT2 regulated the maintenance of stem cell-like properties in oral squamous cell carcinoma. Conclusion ECT2 is highly expressed in oral squamous carcinoma, and it promotes stemness maintenance in oral squamous carcinoma.
SUN Xiaoyan, LI Yi, JIANG Yiqun.
ECT2 Promotes Stemness Maintenance of Oral Squamous Cell Carcinoma[J]. Journal of Hunan Normal University(Medical Science). 2025, 22(5): 1-8
中图分类号：
R739.8
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] PARK J, ZHANG X, LEE S K, et al.CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion[J]. J Clin Invest, 2019, 129(12): 5381-5399. [2] TSAI Y T, CHEN W C, HSU C M, et al.Survival-Weighted Health Profiles in Patients Treated for Advanced Oral Cavity Squamous Cell Carcinoma[J]. Front Oncol, 2021, 11: 754412. [3] LIU Y, SHEN L, LI Y, et al.ETS1-mediated Regulation of SOAT1 Enhances the Malignant Phenotype of Oral Squamous Cell Carcinoma and Induces Tumor-associated Macrophages M2-like Polarization[J]. Int J Biol Sci, 2024, 20(9): 3372-3392. [4] LINGEN M W, KALMAR J R, KARRISON T, et al.Critical evaluation of diagnostic aids for the detection of oral cancer[J]. Oral Oncol, 2008, 44(1): 10-22. [5] SMYTH E C, LAGERGREN J, FITZGERALD R C, et al.Oesophageal cancer[J]. Nat Rev Dis Primers, 2017, 3: 17048. [6] TAN Y, WANG Z, XU M, et al.Oral squamous cell carcinomas: state of the field and emerging directions[J]. Int J Oral Sci, 2023, 15(1): 44. [7] PLAKS V, KONG N, WERB Z.The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?[J]. Cell stem cell, 2015, 16(3): 225-238. [8] KRESO A, DICK J E.Evolution of the cancer stem cell model[J]. Cell Stem Cell, 2014, 14(3): 275-291. [9] BATLLE E, CLEVERS H.Cancer stem cells revisited[J]. Nat Med, 2017, 23(10): 1124-1134. [10] NASSAR D, BLANPAIN C.Cancer Stem Cells: Basic Concepts and Therapeutic Implications[J]. Annu Rev Pathol, 2016, 11: 47-76. [11] WANG Q, LIANG N, YANG T, et al.DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer[J]. J Hepatol, 2021, 75(5): 1142-1153. [12] SHIBUE T, WEINBERG R A. EMT, CSCs,drug resistance: the mechanistic link and clinical implications[J]. Nat Rev Clin Oncol, 2017, 14(10): 611-629. [13] LATHIA J D, MACK S C, MULKEARNS-HUBERT E E, et al. Cancer stem cells in glioblastoma[J]. Genes Dev, 2015, 29(12): 1203-1217. [14] JUSTILIEN V, LEWIS K C, MURRAY N R, et al.Oncogenic Ect2 signaling regulates rRNA synthesis in NSCLC[J]. Small GTPases, 2019, 10(5): 388-394. [15] COOK D R, KANG M, MARTIN T D, et al.Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth[J]. Cancer Res, 2022, 82(1): 90-104. [16] YI M, ZHANG D, SONG B, et al.Increased expression of ECT2 predicts the poor prognosis of breast cancer patients[J]. Exp Hematol Oncol, 2022, 11(1): 107. [17] JUSTILIEN V, ALI S A, JAMIESON L, et al.Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma[J]. Cancer Cell, 2017, 31(2): 256-269. [18] IYODA M, KASAMATSU A, ISHIGAMI T, et al.Epithelial cell transforming sequence 2 in human oral cancer[J]. PloS one, 2010, 5(11): e14082. [19] ZHANG Y, TSENG J T, LIEN I C, et al.mRNAsi Index: Machine Learning in Mining Lung Adenocarcinoma Stem Cell Biomarkers[J]. Genes (Basel), 2020, 11(3): 257. [20] ZHENG F, ZHANG S, CHANG A E, et al.Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy[J]. Int J Biol Sci, 2025, 21(4): 1819-1836. [21] CSCs and pluripotent/multipotent stem cells[J]. Mod Pathol, 2017, 30(10): 1336-1337. [22] LI C, LIANG Y, CAO J, et al.The Delivery of a Wnt Pathway Inhibitor Toward CSCs Requires Stable Liposome Encapsulation and Delayed Drug Release in Tumor Tissues[J]. Mol Ther, 2019, 27(9): 1558-1567. [23] PAN S, ZHAN Y, CHEN X, et al.Identification of Biomarkers for Controlling Cancer Stem Cell Characteristics in Bladder Cancer by Network Analysis of Transcriptome Data Stemness Indices[J]. Front Oncol, 2019, 9: 613. [24] CHEN E, ZOU Z, WANG R, et al.Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies[J]. Front Immunol, 2024, 15: 1244392. [25] ARAMINI B, MASCIALE V, ARIENTI C, et al.Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments[J]. Cancers (Basel), 2022, 14(10): 2408. [26] SILVER D J, LATHIA J D.Go, cancer stem cell, go! CSCs overcome myelin inhibition to move within white matter pathways[J]. Brain, 2021, 144(2): 357-360. [27] MODI S J, KULKARNI V M.Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma[J]. Eur J Med Chem, 2020, 207: 112851. [28] WENG M, LI T, ZHAO J, et al.mRNAsi-related metabolic risk score model identifies poor prognosis, immunoevasive contexture, and low chemotherapy response in colorectal cancer patients through machine learning[J]. Front Immunol, 2022, 13: 950782. [29] FU S, TAN Z, SHI H, et al.Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer[J]. NPJ Precis Oncol, 2024, 8(1): 14. [30] LIU J, WU Z, SUN R, et al.Using mRNAsi to identify prognostic-related genes in endometrial carcinoma based on WGCNA[J]. Life Sci, 2020, 258: 118231. [31] XU D, WANG Y, WU J, et al.ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2/PLK1/PTEN pathway[J]. Cell Death Dis, 2021, 12(2): 162. [32] HE H, LIANG L, JIANG S, et al.GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas[J]. Cell Death Dis, 2024, 15(3): 205. [33] HARA T, ABE M, INOUE H, et al.Cytokinesis regulator ECT2 changes its conformation through phosphorylation at Thr-341 in G2/M phase[J]. Oncogene, 2006, 25(4): 566-578. [34] KOSIBATY Z, MURATA Y, MINAMI Y, et al.ECT2 promotes lung adenocarcinoma progression through extracellular matrix dynamics and focal adhesion signaling[J]. Cancer Sci, 2021, 112(2): 703-714.
PDF(4607 KB)
